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Propolis possesses various biological activities such as antibacterial, antifungal, anti-inﬂammatory, anesthetic and antioxidant
properties. A topically applied product based on Brazilian green propolis was developed for the treatment of burns. For such
substance to be used more safely in future clinical applications, the present study evaluated the mutagenic potential of topical
formulationssupplemented with green propolis extract (1.2,2.4 and 3.6%) based onthe analysisof chromosomalaberrations and
of micronuclei. In the in vitro studies, 3-h pulse (G1 phase of the cell cycle) and continuous (20h) treatments were performed.
In the in vivo assessment, the animals were injured on the back and then submitted to acute (24h), subacute (7 days) and
subchronic (30 days) treatments consisting of daily dermal applications of gels containing diﬀerent concentrations of propolis.
Similar frequencies of chromosomal aberrations were observed for cultures submitted to 3-h pulse and continuous treatment
with gels containing diﬀerent propolis concentrations and cultures not submitted to any treatment. However, in the continuous
treatment cultures treated with the 3.6% propolis gel presented signiﬁcantly lower mitotic indices than the negative control. No
statistically signiﬁcant diﬀerences in the frequencies of micronuclei were observed between animals treated with gels containing
diﬀerent concentrations of propolis and the negative control for the three treatment times. Under the present conditions, topical
formulationscontaining diﬀerent concentrations of green propolis used for the treatment of burns showed no mutagenic eﬀect in
either test system, but 3.6% propolis gel was found to be cytotoxic in the in vitro test.
1.Introduction
Injuries caused by burns are the third most frequent cause of
accidental death in all age groups, with 75% of these lesions
resulting from the victim’s action and occurring at home. In
the United States, 70000 individuals are hospitalized every
year with severe injuries caused by thermal trauma [1].
Burns are caused by physical (temperature, radiation and
electricity) and chemical agents (acids and alkalis), and vary
in degree according to the intensity or concentration of the
causal agents and extent of exposure [2].
The skin is a biological interface between the environ-
ment and organism and represents the ﬁrst line of defense
against external noxious stimuli such as ultraviolet light,
visible irradiation, pro-oxidant chemicals, infection and ion-
izing radiation [3]. Topical administration of antioxidants
provides an eﬃcient way to improve the endogenous cuta-
neous protection system [4].
A topically applied product based on propolis was de-
veloped using as vehicle a polymeric system consisting of
hydrophilic poly(oxyethylene)-poly(oxypropylene)-poly(ox-
yethylene) polymers (Poloxamer 407), inert and atoxic
substances able to generate thermoresistant gel-like colloidal
solutions in the presence of water, with the latter aﬀecting
the behavior of the solution and the molecular diﬀusion of
t h ea c t i v es u b s t a n c e[ 5, 6]. The low toxicity and reduced skin2 Evidence-Based Complementary and Alternative Medicine
irritation of Poloxamer 407 encouraged the evaluation of
potential dermatological applications of these gels, particu-
larlyinthetreatmentofburns[7],inviewoftheiradvantages
such as easy application and removal of the preparation,
as well as the possibility of maintaining the therapeutic
concentration at the site of application. A surgically induced
injurywasfoundtobecompletelyhealedwithin aperiodof7
days. Inaddition, gelcontaining 3.6% propolisled toevident
epithelial reconstruction after 3 days, with the observation of
organized connective tissue ﬁbers and numerous ﬁbroblasts
[8].
Propolis is produced by bees from plant resins and exu-
dates, and its colour, consistency and chemical composition
are intimately related to the ﬂora visited by the bees and
to the season during which it is collected [9]. At present,
more than 300 compounds, mainly polyphenols, have been
i d e n t i ﬁ e da sc o n s t i t u e n t so fp r o p o l i s[ 10]. Most polyphenols
are ﬂavonoids, followed by phenolic acids, esters, aldehydes,
ketones, and so forth. [11]. Propolis possesses various
biological activities such as anti-inﬂammatory [12], antibac-
terial [13], antifungal [14], anesthetic [15] and antioxidant
properties [16, 17]. In addition, it has been used in topical
applications as a tissue regenerating agent, which is one of its
mostpopularusesintheworldtoday[18].However,propolis
contains some compounds which are toxic and induce
hypersensitivity reactions. The main target organ is the skin,
with contact dermatitis being a common manifestation [19].
The mechanisms responsible for the improvement of
health conditions observed with the use of propolis in folk
medicinearestillunknown.Toguaranteethesafeapplication
of propolis in the pharmaceutical industry, it is important to
determine whether topical formulations supplemented with
greenpropolisextract used forthetreatment ofburnsinduce
DNA damage. Therefore, the aim of the present study was
to assess the possible mutagenic eﬀect of these formulations
by in vitro analysis of chromosomal aberrations in Chinese
hamster ovary (CHO) cells and by the in vivo micronucleus
test in Wistar rats.
2.Materialsand Methods
2.1. Preparation of Test Formulations Containing Propolis
Extract. The topical formulations containing standard green
propolis extract (SPE-AF) used for the treatment of burns
were provided by Apis Flora Comercial e Industrial Ltda.,
Ribeir˜ ao Preto, S˜ ao Paulo State, Brazil (Patent number PI
0405483-0, published in Revista de Propriedade Industrial
no 1778 from January 02, 2005). Green propolis extract was
prepared from propolis in natura produced in the region
of Oliveira (State of Minas Gerais, Brazil), a region rich in
native Baccharis dracunculifolia. The gels were prepared on a
weight basis using the cold method according to Schmolka
(1972). Concentrations of Poloxamer 407 and of SPE-AF are
expressed aspercentweight (w/v).Anappropriateamountof
Poloxamer407 wasslowly added tocolddistilled water(5◦C)
under constant stirring. The polymer dispersion was kept in
the refrigerator until a clear solution had been formed (6–
12h). Appropriate amounts of SPE-AF and polyoxyl castor
oil were prepared to yield 1.2, 2.4 and 3.6% (w/v) of dry
propolis extract and then dissolved in the cold solution. Two
controlsampleswereprepared,oneconsistingofthepolymer
dispersion and the other of the solubilizing agent used to
obtain a clean gel.
2.2. Analysis of Propolis Extract by HPLC. The chromato-
graphic analysis of green propolis extract was performed
using a High Performance Liquid Chromatograph (HPLC)
Shimadzu equipped with controller SCL-10Avp,t h r e e
pumps LC-10AD, detector diode-array model SPD-M10Avp
and software controller Shimadzu Class-VP version 5.02. A
Shim-Pack CLC-ODS (M), Shimadzu column (4.6mm ×
250mm, particle diameter of 5μm, pore diameter of 100 ˚ A)
was used. The mobile phase consisted of a buﬀer solution in
pump A (93.9% water, 0.8% acetic acid, 0.3% ammonium
acetate, 5% methanol) and acetonitrile in pump B. The
elution was undertaken using a linear gradient of 25–100%
of B in 60 min at a ﬂow-rate of 1.0mLmin−1. Detection was
performed at 280nm.
The phenolic compounds were identiﬁed by comparison
with the authentic chromatographic standards available at
the compounds library of the Pharmacognosy Laboratory of
the School of Pharmacy of Ribeir˜ ao Preto, S˜ ao Paulo, Brazil,
comparing UV spectra and considering both the maximum
lambda and the relative area obtained with the use of two
wavelengths (A280/320).
The crude propolis extract was dissolved in methanol
(HPLC grade) to obtain a concentration of 1mgmL−1.
Beforeanalysis, all samples were centrifugedat1300rpmand
ﬁltered through a 45-μmﬁ l t e r .
2.3. Chromosomal Aberrations Assay in CHO Cells. CHO9
cells were kindly supplied by the Laboratory of Cytogenetics
and Mutagenesis, University of S˜ ao Paulo, Ribeir˜ ao Preto,
S˜ ao Paulo, Brazil. Cells were maintained as monolayers
in plastic culture ﬂasks (25cm2)i nH A M - F 1 0( S i g m a -
Aldrich, St. Louis, MO, USA) and D-MEM (Sigma-Al-
drich) (1:1) culture media supplemented with 10% fetal
bovine serum (Nutricell), antibiotics (0.01mgmL−1 strep-
tomycin and 0.005mgmL−1 penicillin; Sigma-Aldrich), and
2.38mgmL−1 HEPES (Sigma-Aldrich), at 37
◦Ci naB O D
type chamber.
Exponentially growing CHO cells were seeded (1 × 106
cells per ﬂask) and allowed to grow for 20h (approximately
1.5 times the normal cell cycle) [20]. The cultures were
treated with 5mgmL−1 of each gel containing diﬀerent
concentrations of propolis (1.2, 2.4 and 3.6%), with this
being the concentration limit speciﬁed by guidelines for
cases in which the molecular weight is unknown or mixtures
are being tested. Two treatment protocols were used: 3-
h pulse treatment and continuous (20h) treatment. After
the 3-h pulse treatment, the cells were washed twice in
phosphate-buﬀered saline, fresh medium was added and the
cultures were incubated at 37
◦C for an additional 17h. In
continuous treatment, CHO cells were seeded and treated
until harvest. The cells were ﬁxed 20h after the beginning of
treatment in both protocols. Doxorubicin (DXR, PharmaciaEvidence-Based Complementary and Alternative Medicine 3
Brasil Ltda., S˜ ao Paulo, Brazil) was added to the cultures at
concentrationsof1.0and2.0μgmL −1 forthecontinuousand
3-h pulse treatment, respectively, as positive control. Three
independent replicates were carried out for each treatment.
Colcemid (Demecolcine, 0.1μgmL −1;S i g m a - A l d r i c h )
was added to the culture medium 2h before ﬁxation. At
harvest, the cells were trypsinized (0.025%) and then hypo-
tonized in 1% sodium citrate solution at 37◦Cf o r3 0m i n .
The cells were ﬁxed in methanol/acetic acid (3:1) and the
slides were stained with 5% Giemsa for 5min.
For the determination of chromosomal aberrations, 100
metaphases were analyzed per culture, for a total of 300
cells per treatment and control, and the aberrations were
classiﬁed according to Savage [21]. The mitotic index (MI)
corresponds to the number of metaphase cells among 2000
cells analysed per culture and is reported as percentage. The
MI is expressed as the mean of three replicates. The data
obtained were analysed statistically by ANOVA for repeated
measures, followed by the Tukey test, with the level of
signiﬁcance set at α = 0.05. Gaps were recorded but not
included in the statistical analysis since their cytogenetic
signiﬁcance has not been well established.
2.4. Micronucleus Assay in Wistar Rats. For the experiments,
30 male Wistar rats (Rattus norvegicus, Berkenout, 1769)
with an initial body weight of 45g, obtained from the
Central Animal House, Faculty of Medicine of Ribeir˜ ao
Preto, University of S˜ ao Paulo, Brazil, were allocated to
three treatment times: acute (24h), subacute (7 days) and
subchronic (30 days). The study protocol was approved by
the Ethics Committee for Animal Care of the University of
Franca (process 121/05).
Since the topical formulation used in the present study is
aimed at the treatment of burn injuries, a lesion was created
with a punch on the back of animals previously anesthetized
by intraperitoneal administration of ketamine, midazolam
and acepram [22].
The concentrations of the propolis extract added to the
topical formulations used in the present study, as well as
the treatment protocol, were established based on previous
histological studies regarding the healing eﬀect of the gel
[8]. The animals were treated with gels containing the
following concentrations of propolis: 1.2, 2.4 and 3.6% w/v.
In addition, a group of animals treated with propolis-free
gel, a negative control group and a positive control group
(50 mg cyclophosphamide kg−1 body weight) were included.
Eachtreatmentgroupconsistedofﬁveanimals. Thesegroups
weresubmittedtoacute,subacuteandsubchronictreatments
with gels containing propolis or not, with the animals being
t r e a t e da n dw e i g h e dd a i l y .
The frequency of micronuclei was determined in periph-
eral blood of Wistar rats according to the technique of Mac-
Gregor et al. [23]. Peripheral blood smears were obtained
24h and 7 and 30 days after the beginning of application of
the gels to the dorsal lesions of the animals. The frequency
of micronucleated polychromatic erythrocytes (MNPCEs)
was determined based on the analysis of 2000 anucleated
polychromatic erythrocytes (PCE) per animal. A total of 400
erythrocytesperanimalwere scoredtodeterminethenuclear
division index (NDI, PCE/PCE + NCE [normochromatic
erythrocytes]).
Diﬀerences in the frequencies of MNPCEs and NDI
between groups treated with the diﬀerent propolis gels at the
three exposure times were analysed statistically by the Tukey
test, with the level of signiﬁcance set at α = 0.05.
3.Results
3.1. Analysis of Propolis Extract by HPLC. HPLC analysis of
green propolis extract permitted the identiﬁcation of the fol-
lowing compounds: (i) p-coumaric acid; (ii) aromadendrin-
4 -methyl ether; (iii) 3-prenyl-p-coumaric acid (drupanin);
(iv) 3,5-diprenyl-p-coumaric acid (artepillin C) and (v)
baccharin (Figure 1).
3.2. Chromosomal Aberrations Assay in CHO Cells. The
results obtained for the 3-h pulse and continuous treatments
using gels with diﬀerent concentrations of propolis and their
respective controls are shown in Table 1. Cultures submitted
to 3-h pulse treatment with gels containing 1.2 and 2.4%
propolis showed a small increase in the number of chromo-
somal aberrations and altered metaphases compared to the
control group, but these diﬀerences were not statistically sig-
niﬁcant.Inthecontinuoustreatment,gelscontaining2.4and
3.6% propolis presented slightly higher frequencies of chro-
mosomal aberrations and altered metaphases than the nega-
tive control but the diﬀerence was not signiﬁcant (P > .05).
No signiﬁcant diﬀerences in the MI were observed
between cultures submitted to 3-h pulse treatment with
gels containing diﬀerent propolis concentrations and their
respective controls. In the continuous treatment, lower MI
were observed for cultures treated with gels containing 2.4
and 3.6% propolis when compared to control, but this
decrease was only signiﬁcant (P > .05) for the 3.6% propolis
gel (Table 1).
3.3. Micronucleus Assay in Wistar Rats. Table 2 shows the
mean initial body weight, ﬁnal body weight and body weight
gain during the experimental period. No statistically signif-
icant diﬀerences in these variables were observed between
groups (P > .05).
The frequencies of MNPCEs in peripheral blood of ani-
malssubmittedtoacute,subacuteandsubchronictreatments
with gels containing diﬀerent propolis concentrations are
shown inTable 3. Animals submitted toacutetreatment with
1.2% propolis gel showed a lower frequency of MNPCEs
compared to the other groups, but this diﬀerence was not
statistically signiﬁcant. In the subacute treatment, no dif-
ference in the frequency of MNPCEs was observed between
the groups receiving propolis gels and the negative control.
In the subchronic treatment, comparison of the frequency
between the negative control and the other groups showed a
lower frequency of MNPCEs in the group receiving propolis-
free gel and the group treated with 3.6% propolis gel.
However, these diﬀerences were not signiﬁcant (P > .05).
Thus, acute, subacute or subchronic treatment did not result4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: HPLC chromatographic proﬁle of green propolis extract. (1) p-coumaric acid; (2) aromadendrin-4 -methyl ether; (3)3-prenyl-p-
coumaric acid (drupanin); (4)3 , 5 - d i p r e n y l - p-coumaric acid (artepillin C) and (5) baccharin.
Table 1: Number of abnormal cells and mitotic index (MI) obtained for CHO cells submitted to 3-h pulse or continuous (20h) treatment
with gels containingdiﬀerent concentrations of propolis and their respective controls.
Treatments MI (%) ±SD
c Abnormalcells ±SD
c Aberration frequency
3-h pulse 20h 3-h pulse 20h 3-h pulse 20h
Control 6.05 ± 2.00 6.08 ± 1.32 2.00 ± 2.00 3.00 ± 2.00 0.02 0.03
DMSO
a 4.92 ± 0.40 4.72 ± 2.83 2.00 ± 1.00 3.70 ± 2.34 0.02 0.04
Without propolis 4.26 ± 0.60 5.15 ± 0.02 2.40 ± 1.53 2.70 ± 0.58 0.03 0.03
1.2% Propolis 9.08 ± 0.60 6.77 ± 1.44 4.40 ± 2.52 3.70 ± 4.72 0.04 0.04
2.4% Propolis 8.48 ± 1.27 2.63 ± 1.61 3.70 ± 2.52 5.70 ± 1.15 0.04 0.06
3.6% Propolis 8.13 ± 1.81 0.90 ± 0.52∗ 1.70 ± 0.58 7.00 ± 5.00 0.02 0.07
DXR
b 7.67 ± 1.87 5.97 ± 2.91 15.40 ± 4.16 15.00 ± 2.64 0.15 0.16
One-hundred metaphases were analyzed per culture, for a total of 300 cells per treatment.
aDMSO, dimethylsulfoxide, 0.5μL/mL, bDXR, doxorubicin (1.0 and 2.0μg/mL in continuous and 3-h pulse treatment, resp.), cValues are mean ± SD.
∗Signiﬁcantly diﬀerent from the control group (P<. 05).
inanincreaseinthefrequencyofMNPCEsinanimals treated
with gels containing diﬀerent propolis concentrations when
compared to the negative control or to animals treated with
propolis-free gel.
Comparison of the frequencies of MNPCEs between the
diﬀerent exposure times revealed a nonsigniﬁcant reduction
inalltreatment groupsat7and 30dayscomparedtothe24-h
treatment. Thisdecreaseisprobablyrelated totheadaptation
of the animal to the housing conditions.
Analysis of the NDI obtained for the acute, subacute and
subchronic treatments showed no signiﬁcant diﬀerence in
the ratio of polychromatic erythrocytes to total erythrocytes
between animals treated with gels for burns containing
diﬀerent propolis concentrations and controls.
4.Discussion
From the biological activities found for propolis, the antiox-
idant activity deserves special interest since it suggests
propolis could be successfully applied topically to prevent
and treat skin damages. Recently, propolis extract added
to topical formulations has been shown to maintain its
antioxidant activity, protecting skin against damage caused
by free radicals [16].
The antioxidant activity ofgreen propolishas beeninves-
tigated by Sim˜ oes et al. [24], who studied the biological
eﬀects of diﬀerent extracts and fractions of green propolis.
A correlation was observed between the antioxidant activity
and chemical composition of its diﬀerent fractions, with
special emphasis on the presence of ﬂavonoids and p-
coumaric acid derivatives. The authors concluded that the
components of propolis act through diﬀerent mechanisms
sequestering reactive oxygen species. Artepillin C (3,4-dipre-
nyl-p-coumaric acid), a major constituent of green propolis,
is also an excellent scavenger of free radicals similar to
catechins [25].
Tavares et al. [26] studied the mutagenic and antimuta-
genic eﬀects of the green propolis on CHO cells. The authors
showed that, on the one hand, the highest propolis con-
centration tested resulted in a small but signiﬁcant increase
in the frequency of chromosomal aberrations whereas, on
the other hand, the lowest concentration tested signiﬁ-
cantly reduced the chromosome damage induced by the
chemotherapeutic agent DXR. These results indicate that
green propolis possesses the characteristics of a “Janus”
substance, that is, propolis is mutagenic at higher concentra-
tions, while at lower concentrations it exerts a chemopreven-
tive eﬀect on DXR-induced mutagenicity. Ozkul et al. [27]Evidence-Based Complementary and Alternative Medicine 5
Table 2: Mean initial body weight, ﬁnal body weight and body weight gain of rats and their respective control after 30 days of treatment
with gels containingdiﬀerent concentrations of propolis.
Treatments (n = 5 rats/group) Initial body weight (g)
a Final body weight (g)
a Body weight gain (g)
a
Control 51 ± 6 322 ± 7 270 ± 6
Without propolis 47 ± 9 276 ± 11 229 ± 16
1.2% Propolis 48 ± 9 257 ± 25 209 ± 23
2.4% Propolis 51 ± 10 262 ± 38 211 ± 32
3.6% Propolis 50 ± 7 288 ± 49 239 ± 43
aValues are mean ± SD.
Table 3: Frequency of micronucleated polychromatic erythrocytes (MNPCEs) and nuclear division index (NDI) in peripheral blood of
male Wistar rats submitted to acute, subacute and subchronic treatments with gels containing diﬀerent concentrations of propolis and their
respective controls.
Treatments (n = 5r a t s / g r o u p ) Acute Subacute Subchronic
MNPCEs
a NDI
b MNPCEs
a NDI
b MNPCEs
a NDI
b
Control 0.24 0.18 ± 0.06 0.09 0.14 ± 0.03 0.10 0.12 ± 0.02
Without propolis 0.32 0.21 ± 0.08 0.08 0.14 ± 0.04 0.03 0.10 ± 0.03
1.2% Propolis 0.06 0.20 ± 0.05 0.09 0.16 ± 0.03 0.06 0.13 ± 0.02
2.4% Propolis 0.28 0.16 ± 0.04 0.15 0.17 ± 0.05 0.05 0.12 ± 0.03
3.6% Propolis 0.28 0.20 ± 0.03 0.15 0.13 ± 0.02 0.03 0.12 ± 0.02
CPA
a 0.89 0.15 ± 0.03 0.89 0.15 ± 0.03 0.89 0.15 ± 0.03
A total of 2000 cells were analyzed per animal, for a total of 10000 cells per treatment.
aCPA, cyclophosphamide (50mg/kg body weight), bValues are percentage, cValues are mean ± SD.
alsoreportedmutageniceﬀectofpropoliswhentestedathigh
concentrations in human lymphocytes.
In the present study, the topical formulations supple-
mented with green propolis extract for the treatment of
burns were assessed in vitro for their mutagenic eﬀect on
CHO cells and in vivo for their capacity to induce micronu-
clei in peripheral blood. The results obtained in the in vitro
assay showed that 3-h exposure to these topical formulations
did not produce any signiﬁcant increase in chromosomal
aberrations. According to Galloway et al. [20], in the case
of a negative result in the 3-h pulse treatment, continuous
treatment should be performed. Thus, we submitted CHO
cellstocontinuoustreatmentafterobtaininganegativeresult
in the 3-h pulse treatment. Similarly, 20-h treatment with
propolis gels did not result in an increase of chromosomal
aberrations compared to the control culture.
Regarding the test system used in the present study, it
should be emphasized that the chromosomal aberrations
assay in mammalian cell cultures is one of the most widely
used methods for the assessment of mutagenic and/or car-
cinogenic agents [28]. The sensitivity of the test system was
demonstrated by the observation of a signiﬁcant increase in
chromosomal aberrations produced by the positive control
substance (DXR) and by the fact that negative control values
were within the range reported for the CHO in vitro test
system.
Analysis of the MI showed that gels containing diﬀerent
concentrations of propolis presented no cytotoxic eﬀect,
except for the 3.6% propolis gel which was cytotoxic in the
continuous treatment. A nonsigniﬁcant increase in the num-
ber of chromosomal aberrations was also observed in this
treatment. According to Galloway et al. [20], an increased
osmolarity of the culture medium may cause an increase in
thenumberofchromosomalaberrations.Thus,theincreased
frequency of chromosomal aberrations observed might be
related to the cytotoxicity of gel containing 3.6% propolis.
This cytotoxicity might be explained in part by the presence
of artepillin C, the most abundant compound identiﬁed
(Figure 1), which has shown in vitro cytotoxic activity in
some cell lines. The observed cytotoxicity seemed to be
partly attributable to the induction of apoptosis-like DNA
fragmentation [29].
It is known that many compounds can yield negative
in vitro results and positive in vivo results because of their
indirect action and consequent need for metabolic activa-
tion. Furthermore, the possibility that many of these positive
results may not be relevant in terms of human exposure [30]
should be taken into account. For this reason, in addition
to the in vitro test, the topical formulations supplemented
with green propolis extract for the treatment of burns
were also tested for their capacity to induce micronuclei
in vivo in rat peripheral blood. The results obtained with
the in vivo test system showed that these gels did not
increase the frequency of MNPCEs in peripheral blood of
rats submitted to acute, subacute or subchronic treatment.
Some considerations regarding the test system used in the
present study are important. The micronucleus test is the
most widely used in vivo assay for the identiﬁcation of
clastogenic and aneugenic agents, and is conducted using
the bone marrow or peripheral blood of rodents [31]. In
this study the rat peripheral blood was employed because
previous histological studies regarding the healing eﬀect of6 Evidence-Based Complementary and Alternative Medicine
thegelscontainingdiﬀerentconcentrationsofgreen propolis
were performed using this species [8].
According to Abramsson-Zetterberg et al. [32], since rats
have been used as an animal model in conventional tox-
icological studies, parallel application of the micronucleus
t e s tm a yb ea d v a n t a g e o u sa sa ni n d i c a t i o no ft h eg e n o t o x i c
eﬀect in this species. In the case of prolonged exposure of
rats, a species commonly used in toxicological tests, various
peripheral blood samples for the micronucleus test can be
obtained from the same animal. Analysis of micronucleated
cells in peripheral blood samples obtained at various times
along the experiment provides important supplementary
information regarding the time that has elapsed since the
induction of micronuclei.
With respect to the route of administration used in the
present study, it is important to emphasize that MNPCE
analysis is adequate for the assessment of the possible
mutagenicity of gels containing diﬀerent concentrations of
green propolis and applied dermally. Itoh et al. [33]u s e dt h e
same test system fortheevaluationoftheantimicrobial agent
quinolone applied dermally to mice. The results showed
that the method was a useful tool for the detection of in
vivo chromosome breaks and for the investigation of the
photochemical carcinogenesis of chemicals. Vijayalaxmi et
al. [34] observed that jet fuels did not have the potential
to induce genotoxicity based on micronucleus studies in the
peripheral blood and bone marrow of mice treated dermally.
TheincreasedfrequencyofMNPCEsobservedinanimals
treated with the known clastogenic agentcyclophosphamide,
used as positive control in the present study, indicates that
this test system should reveal an increase in the frequen-
cies of MNPCEs in animals treated with gels containing
diﬀerent concentrations of green propolis if the latter were
mutagenic. The absence of mutagenicity in rat peripheral
blood erythrocytes suggests that these gels are not muta-
genic or they are not absorbed systemically when applied
dermally.
In the present study, the in vivo micronucleus assay
conﬁrmed that the topical formulations supplemented with
green propolis extract have no mutagenic eﬀect as demon-
strated in the in vitro test.
In conclusion, under the present conditions topical
formulations supplemented with green propolis extract used
for the treatment of burns showed no mutagenic eﬀect in
either test system, but 3.6% propolis gel was cytotoxic in
the in vitro test. The present results contribute to a better
understanding of the action of propolis on the human
organism, and consequently permit the safer use of topical
formulations supplemented with green propolis extract in
future clinical applications.
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